by IR Team | Jun 2, 2022 | Press Release
AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, today announced the launch of its new mobile-optimized website designed to provide doctors, researchers...
by IR Team | Apr 11, 2022 | News
The challenge has been in early detection of inflammation. Matrix metalloproteinase-9 (MMP-9), an inflammatory biomarker consistently elevated in the tears of dry eye patients, may accelerate early diagnosis when detected. AXIM Biotechnologies, Inc. recently announced...
by IR Team | Apr 8, 2021 | News
Axim Biotechnologies has developed a rapid quantitative tear test to detect an inflammatory biomarker for dry eye disease, according to a press release. Diagnosis and treatment of dry eye disease (DED) can be difficult because of the discordance between signs and...
by IR Team | Mar 24, 2021 | News
AXIM Biotechnologies Inc. (AXIM.OB) said that its manufacturing partner, Empowered Diagnostics, has filed an Emergency Use Authorization or EUA application with the US Food and Drug Administration for the approval to use ImmunoPass, the company’s rapid test that...
by IR Team | Mar 24, 2021 | Press Release
SAN DIEGO – March 24, 2021 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company’s manufacturing partner,...
